TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1-Reference-Cited by-同舟云学术

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

Published:2017-03-09 Issue:10 Volume:129 Page:1284-1295
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Jahn Lorenz¹^ORCID,Hombrink Pleun¹²,Hagedoorn Renate S.¹,Kester Michel G. D.¹,van der Steen Dirk M.¹,Rodriguez Tania³,Pentcheva-Hoang Tsvetelina³,de Ru Arnoud H.⁴,Schoonakker Marjolein P.¹,Meeuwsen Miranda H.¹,Griffioen Marieke¹,van Veelen Peter A.⁴,Falkenburg J. H. Frederik¹,Heemskerk Mirjam H. M.¹

Affiliation:

1. Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;

2. Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands;

3. Research and Development, Bellicum Pharmaceuticals, Inc., Houston, TX;

4. Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands

Abstract

Key Points Isolation and characterization of a high-affinity TCR targeting the intracellular B cell–specific transcription factor BOB1. T cells expressing a BOB1-specific TCR lysed and eradicated primary multiple myeloma and other B-cell malignancies in vitro and in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/10/1284/1399333/blood737536.pdf

Reference49 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

3. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011

4. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998

5. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma;Vose;J Clin Oncol,2001

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Approaches in Gastric Cancer Immunotherapy;Gastric Cancer - Progress and Challenges in the Era of Precision Medicine [Working Title];2024-07-01

2. Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence;Frontiers in Immunology;2024-04-16

3. Reassessing human MHC-I genetic diversity in T cell studies;Scientific Reports;2024-04-04

4. The Scientific Rationale for Targeting Tumor‐Associated Antigens;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

5. Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications;Chinese Medical Journal;2024-01-25